

GE Healthcare

Amersham
Interleukin-1 Alpha
[(m)IL-1 α] Mouse,
Biotrak ELISA System
96 wells

Product Booklet

Code: RPN2719



Page finder

1. Legal	3
2. Handling	4
2.1. Safety warnings and precautions	4
2.2. Storage	4
2.3. Expiry	4
3. Components of the assay system	5
4. Critical parameters	6
5. Description	7
5.1. Summary of the assay	7
6. Additional materials and equipment required	9
7. Sample preparation	10
8. Assay procedure	11
8.1. Reagent preparation	11
8.2. Preparation of standard curve	12
8.3. Running partial plates	12
8.4. Assay protocol	13
9. Data processing	16
9.1. Calculation of results	16
9.2. Typical assay data	16
10. Additional information	18
10.1. Specificity	18
10.2. Reproducibility	18
10.3. Sensitivity	18
10.4. Parallelism	18
10.5. Recovery	18
10.6. Expected values	19
10.7. Background and references	19
10.8. Related products	20

1. Legal

GE and GE monogram are trademarks of General Electric Company.
Amersham and Biotrak are trademarks of GE Healthcare companies.

© 2006 General Electric Company – All rights reserved.

GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specification and features shown herein, or discontinue the product described at any time without notice or obligation.

Contact your GE Healthcare representative for the most current information and a copy of the terms and conditions.

<http://www.gehealthcare.com/lifesciences>

GE Healthcare UK Limited.
Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA UK

2. Handling

2.1. Safety warnings and precautions

Warning: For research use

only. Not recommended or intended for diagnosis of disease in humans or animals. Do not use internally or externally in humans or animals.

All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.

2.2. Storage

Store at 2–8°C.

2.3. Expiry

The expiry date is stated on the package and will normally be at least 4 weeks from the date of despatch

3. Components of the assay system

This pack contains the following assay components, sufficient material for 96 wells.

All reagents are stored refrigerated at 2–8°C. Refer to the expiry date on the kit box.

(m)IL-1 α microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody against IL-1 α .

Biotinylated antibody reagent - antibody against mouse IL-1 α conjugated to biotin, with 0.1% (w/v) sodium azide, 8 ml.

Streptavidin-HRP concentrate - streptavidin conjugated to HRP, 75 μ l

Streptavidin-HRP dilution buffer - 14 ml

(m)IL-1 α standard - 2 vials of recombinant mouse IL-1 α , lyophilized.

Standard diluent- with 0.1% (w/v) sodium azide, 12 ml.

Wash buffer concentrate - 30-fold concentrated solution, 50 ml.

Pre-mixed TMB substrate reagent - with methanol.

Stop solution - 0.18 M sulfuric acid, 14 ml.

Plate covers - 4 adhesive strips.

4. Critical parameters

- Allow samples and all reagents to reach room temperature prior to performing the assays. Do not use water baths to thaw samples or reagents.
- Mix samples and all reagents thoroughly before use.
- Avoid excessive foaming of reagents. Also avoid exposure of reagents to excessive heat or light during storage and incubation.
- Avoid handling the tops of the wells both before and after filling.
- Standards and samples should be assayed in duplicate.
- Run a separate standard curve for each assay.
- The total dispensing time for each plate should not exceed 20 minutes.
- Use only coated wells from the same reagent batch for each assay. Also do not mix reagents from different kit lots.
- Some components of this kit contain sodium azide which may react with lead and copper plumbing to form explosive metallic azides. Flush with large volumes of water during disposal.

5. Description

The Biotrak™ mouse interleukin-1 α ELISA system from GE Healthcare provides a simple, specific, reliable and precise quantitative determination of (m)IL-1 α in cell culture supernatants, plasma, serum and urine.

The assay system is based on a solid phase ELISA, which utilizes a monoclonal antibody for (m)IL-1 α bound to the wells of a microplate together with a biotinylated antibody to (m)IL-1 α and streptavidin conjugated to horseradish peroxidase. Although the Biotrak (m)IL-1 α immunoassay contains recombinant (m)IL-1 α and antibodies raised against recombinant (m)IL-1 α it has been shown to quantitate accurately both natural (m)IL-1 α and recombinant (m)IL-1 α .

(m)IL-1 α can be measured in the approximate range of 15.6–1000 pg/ml (0.78–50 pg/well) in less than 3.5 hours using the protocol provided with the kit. Each pack contains sufficient material for 96 wells. If one standard curve is constructed, 43 unknowns can be measured in duplicate.

- High sensitivity - 6 pg/ml (0.3 pg/well)
- Same day protocol
- Pre-coated plate
- Specific for (m)IL-1 α

5.1. Summary of the assay

This assay employs the quantitative *in vitro* enzyme linked immunosorbent technique. A monoclonal antibody specific for (m)IL-1 α has been coated on the microplate provided in the kit. Samples are pipetted into the wells along with biotinylated antibody reagent. If present, the (m)IL-1 α is bound by both the immobilized and the biotinylated antibody. After washing away any unbound sample proteins and biotinylated antibody, a streptavidin-HRP conjugate is added to the wells.

Any (m)IL-1 α which was bound by both the immobilized and the biotinylated antibody during the first incubation will be bound by the streptavidin conjugate. Following a wash to remove unbound conjugate, a substrate solution is added to the wells and color develops in proportion to the amount of (m)IL-1 α bound in the initial step.

In addition to the samples to be tested, a series of wells is prepared using known concentrations of the (m)IL-1 α standard. A curve, plotting the optical density versus the concentration of (m)IL-1 α in these standard wells, is prepared. By comparing the optical density of the samples to this standard curve, the concentration of the (m)IL-1 α in the unknown samples is then determined.

6. Additional materials and equipment required

The following materials and equipment are required:

- Pipettes or pipetting equipment with disposable tips (50 μ l, 100 μ l and 1.00 ml)
- Disposable polypropylene test tubes - do not use polystyrene, polycarbonate or glass
- Measuring cylinders 2 l and 20 ml
- Distilled or deionized water
- Plate reader capable of reading at 450 nm

Optional equipment

Assays may be performed with commercially available microplate washers to aid convenience and assay throughput.

7. Sample preparation

Cell culture supernatants

Centrifuge to remove any particulate material and store at -15°C to -30°C. Avoid freeze-thaw cycles.

Serum

Serum samples should be allowed to clot at room temperature. Immediately after clotting, spin down. Specimens should be clear and non-hemolyzed whenever possible. If samples contain particulate matter, clarify by centrifugation before testing.

Serum, plasma and cell culture supernatant samples that are to be assayed within 24 hours should be stored at 2–8°C. Specimens to be stored for longer periods of time should be frozen at -70°C to avoid loss of biologically active cytokine. Avoid freezing and thawing samples more than once.

8. Assay procedure

8.1. Reagent preparation

Wash buffer concentrate

Any precipitate formed during storage will redissolve upon dilution. Dilute 30-fold to prepare 1500 ml of wash buffer. Store at 2–8 °C until the expiry date of the kit. Do not use wash buffer if it becomes visibly contaminated on storage.

Streptavidin-HRP solution

Prepare the exact amount of streptavidin-HRP solution no more than 15 minutes prior to use.

Do not store prepared streptavidin-HRP solution

The streptavidin-HRP concentrate may require spinning down to force the contents to the bottom of the vial. Add 30 µl of streptavidin-HRP concentrate to 12 ml streptavidin-HRP dilution buffer in a plastic 15 ml tube and mix gently. The streptavidin-HRP solution is now ready for use.

If running partial plates, use only the amount of streptavidin-HRP solution required for the number of strips being run. Use 2.5 µl of streptavidin-HRP concentrate and 1 ml of streptavidin-HRP dilution buffer per strip being run.

(m)IL-1 α standard

It is important that the diluent selected for reconstitution and dilution of the standard reflects the environment of the samples being measured. Standard diluent will be suitable for dilution in serum and plasma measurements. If the samples are cell culture supernatants, the culture media used will be suitable for preparation of the standard curve.

Testing of RPMI with different concentrations of fetal bovine serum has shown that this assay is not adversely affected by culture

medium. Therefore when running both culture and serum or plasma samples on the same plate, reconstitute the standard with water and carry out the dilutions in standard diluent. If you are using an unusual type of culture medium, you may wish to validate the medium by running two standard curves in parallel; one diluted in standard diluent and one diluted in culture medium. If the two standard curves are within 10% of the mean for both standard curves then the assay can be run using either curve.

Reconstitute the (m)IL-1 α standard with distilled or deionized water (reconstitution volume is stated on the standard vial label). This reconstitution produces a stock solution of 4000 pg/ml. Mix by gently inverting the vial. Use this stock solution to produce a dilution series, as described below, within the range of this assay (15–1000 pg/ml). Use standards within 60 minutes of dilution.

8.2. Preparation of the standard curve

Label five tubes, one tube for each standard dilution:

1000 pg/ml, 250 pg/ml, 62.5 pg/ml, 15.6 pg/ml and 0 pg/ml. Pipette 300 μ l of appropriate diluent into each tube. Pipette

100 μ l of reconstituted (m)IL-1 α standard into the first tube labelled 1000 pg/ml and mix. Pipette 100 μ l of this dilution into the second tube labelled 250 pg/ml and mix. Repeat this serial dilution twice more to give a standard concentration range of 1000–15.6 pg/ml.

These concentrations, 1000 pg/ml, 250 pg/ml, 62.5 pg/ml and 15.6 pg/ml, together with the zero standard (0 pg/ml), which contains only appropriate diluent, are used to provide the standard curve points.

8.3. Running partial plates

This ELISA provides the flexibility to run two partial plates on separate occasions. Decide the number of strips you wish to run, leaving the strips to be used in the frame. Remove the unnecessary strips and

store them in the foil pouch with the desiccant provided at 2–8°C, making sure the foil pouch is sealed tightly.

When adding the TMB substrate reagent, pour out from the bottle **only** the amount needed to run the first half plate. Do not combine left over substrate with that reserved for the second half of the plate. Care must be taken to ensure that the remaining TMB substrate reagent is not contaminated. If the substrate reagent is bright blue prior to use, it has been contaminated. **DO NOT USE.**

8.4. Assay protocol

1. Prepare assay reagents and working standards as described in the previous sections.
2. Set up the microplate with sufficient wells to enable the running of all standards and samples as required (see figure 1).
3. Remove excess microplate strips from the frame and store in the resealable foil bag.
4. Add 50 µl of biotinylated antibody to each well that is to be used.
5. Add 50 µl of standard or sample per well, adding 50 µl of standard diluent or cell culture medium to the zero standard wells. Cover with adhesive strip provided and incubate for 2 hours at room temperature (20–25°C).
6. Aspirate or decant each well and wash, repeating the process twice for a total of three washes. Wash vigorously by filling each well with wash buffer (~400 µl) using a washbottle, pipette or manifold dispenser. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any remaining wash buffer by inverting the plate and blotting it against clean paper towelling.
7. Add 100 µl of streptavidin-HRP solution. Cover with a new adhesive strip and incubate for 30 minutes at room temperature (20–25°C).
8. Repeat the aspiration/wash step as in step 6.

9. Add 100 μ l of TMB substrate solution into each well, incubate for 30 minutes at room temperature (20–25°C). If the substrate reagent is bright blue prior to use, do not use. **THE PLATE SHOULD BE DEVELOPED IN THE DARK.** Do not cover the plate with aluminium foil or an adhesive strip.
10. Add 100 μ l of stop solution to each well.
11. Determine the optical density of each well within 30 minutes, using a spectrophotometer set to 450 nm.

	1	2	3	4	5	6	7	8	9	10	11	12
A	0	0	S	S	S	S	S	S	S	S	S	S
B	15.6	15.6	S	S	S	S	S	S	S	S	S	S
C	62.5	62.5	S	S	S	S	S	S	S	S	S	S
D	250	250	S	S	S	S	S	S	S	S	S	S
E	1000	1000	S	S	S	S	S	S	S	S	S	S
F	S	S	S	S	S	S	S	S	S	S	S	S
G	S	S	S	S	S	S	S	S	S	S	S	S
H	S	S	S	S	S	S	S	S	S	S	S	S

Figure 1. Recommended positioning of standard (0–1000 pg/ml) and sample (S) wells .

Table 1. Assay protocol (all volumes are in microlitres)

	Zero standard (B₀)	Standards	Samples
Biotinylated antibody reagent	50	50	50
Standard	–	50	–
Standard diluent or cell culture media	50	–	–
Sample	–	–	50
Cover plate, incubate at room temperature (20°C–25°C) for 2 hours.			
Aspirate/decant and wash vigorously all wells three times with ~400 µl wash buffer.			
Streptavidin - HRP concentrate	100	100	100
Cover plate, incubate at room temperature (20–25°C) for 30 minutes.			
Aspirate/decant and wash vigorously all wells three times with ~400 µl wash buffer.			
Substrate	100	100	100
Incubate at room temperature (20–25°C) for 30 minutes in the dark.			
Stop solution	100	100	100
Determine optical density at 450 nm within 30 minutes.			

9. Data processing

9.1. Calculation of results

Average the duplicate readings for each standard, control and sample and subtract the zero standard optical density.

Plot the optical density for the standards versus the concentration of the standards and draw the best curve. The data can be linearized by using a log/log plot and regression analysis may be applied to the log transformation.

Figure 2 shows such a plot of the data from table 2. The standard curve, is provided for illustration only. A standard curve should be generated for each set of samples to be assayed. This allows for the measurements of 43 unknowns in duplicate.

9.2. Typical assay data

The following data (table 2) were obtained for a standard curve using the protocol provided.

Table 2. Typical assay data

Tube	Optical density subtracted	Zero standard
Zero standard	0.050	–
15.6 pg/ml standard	0.079	0.029
62.5 pg/ml standard	0.171	0.121
250 pg/ml standard	0.506	0.456
1000 pg/ml standard	1.700	1.650




Figure 2. Standard curve

10. Additional information

10.1. Specificity

This assay recognises both natural and recombinant (m)IL-1 α . It does not cross-react with (h)IL-1 α , (h)IL-1 β , (m)IL-1 β , (m)IL-3, (m)IL-4, (m)IL-5, (m)IL-7, (m)GM-CSF, (m)TNF α or (m)IFN γ .

10.2. Reproducibility

Within-assay precision

The within-assay coefficient of variation of the ELISA has been determined to be <10%.

Between-assay precision

The between-assay coefficient of variation of the ELISA has been determined to be <10%.

10.3. Sensitivity

The minimum detectable dose of (m)IL-1 α was determined to be 6 pg/ml (0.3 pg/well), by adding two standard deviations to the optical density value of zero and calculating the corresponding concentration from the standard curve.

10.4. Parallelism

Linearity of dilution was determined by serially diluting seven different positive samples. The dilutions were run in the assay and the found doses were plotted against the expected doses.

10.5. Recovery

Recovery in the assay has been determined in serum and various plasma samples by means of spike and recovery studies. An average recovery in serum was determined to be 78.9% $\pm$ 4.7%, and an average recovery in plasma was determined to be 62.7% $\pm$ 2.9%.

10.6. Expected values

The average levels of (m)IL-1 α found in 23 normal serum samples was 23 pg/ml with a range of 0–89 pg/ml. The average level of (m)IL-1 α found in 12 normal plasma samples was 7.5 pg/ml with a range of 0–15 pg/ml.

10.7. Background and references

IL-1 α is one of a group of three related polypeptide hormones that also includes IL-1 β and IL-1ra (receptor antagonist). The IL-1 molecules exert effects on a variety of cell types involved in the host response to injury and infection.

IL-1 α is produced from a 271 amino acid precursor which, although it is biologically active, is generally not secreted. The mature form of IL-1 α is a 153 amino acid protein of 17.5 kDa (determined by SDS-PAGE). Numerous cell types produce IL-1 α including: astrocytes, B cells, endothelial cells, keratinocytes, kidney epithelial cells, monocytes and myeloid cell lines.

IL-1 α can be induced by a variety of agents including: LPS, *S.aureus*, IL-1, leukotrienes, phorbol esters, TNF, C5 α , GM-CSF, indomethacin and zymosan. Agents that inhibit IL-1 α production include: dexamethasone, prednisolone, cAMP, PGE₂, IL-4, IL-10, TGF β , and retinoic acid.

Two distinct IL-1 receptors (IL-1R) have been identified, termed type I (80 kDa) and type II (68 kDa). Both receptors bind IL-1 α and IL-1 β with high affinity ($\sim 10^{-10}$ M). IL-1RI is expressed by T cells, endothelial cells and fibroblasts while IL-1RII is expressed by B cells and other monomyelocytic cell types. Receptor density ranges from 0–30000 per cell with fibroblasts and keratinocytes displaying the highest levels. Both IL-1RI and IL-1RII are members of the Ig superfamily.

Although IL-1 has been demonstrated to play an important role in several *in vivo* phenomena, the detection of IL-1 *in vivo* using

bioassays has been difficult. IL-1 is an endogenous pyrogen and induces fever in animal models. IL-1 is also involved in muscle proteolysis, bone resorption, wound healing, haematopoiesis and inflammatory diseases, including diabetes, periodontitis and rheumatoid arthritis.

1. Dinarello, C.A. *et al.*, *Blood* **77**, 1627 (1991).
2. Cannon, J.G. *et al.*, *J. Infect. Dis.* **161**, 79 (1990).
3. Grassi, J. *et al.*, *J Immunol. Methods* **123**, 193 (1989).
4. Lonnermann, G. *et al.*, *Lymphokine Res.* **7**, 75 (1988).
5. Zucall, J.R. *et al.*, *Blood* **69**, 33 (1987).
6. Dinarello, C.A. *et al.*, *J. Clin. Invest.* **77**, 1743 (1987).
7. Dinarello, C.A. *et al.*, *Year Immunol*, **2**, 68 (1986).
8. Kronheim, S.R. *et al.*, *J. Exp. Med.* **161**, 1490 (1985).

10.8. Related products

Biotrak range of mouse cytokine ELISA systems

Biotrak range of rat cytokine ELISA systems

Biotrak range of human cytokine ELISA systems

Please contact your local GE Healthcare office for full details

Range of unlabelled and radiolabelled growth factors and cytokines

Cell proliferation

Cell proliferation kit (for immunocytochemical/
immunohistochemical measurement)

RPN20

Cell proliferation ELISA

RPN250

Monoclonal anti-bromodeoxyuridine

RPN202

Cell proliferation labelling reagent

RPN201

GE Healthcare offices:

GE Healthcare Bio-Sciences AB
Björkgatan 30 751 84

Uppsala
Sweden

GE Healthcare Europe GmbH
Munzinger Strasse 5 D-79111
Freiburg
Germany

GE Healthcare UK Limited
Amersham Place
Little Chalfont
Buckinghamshire
HP7 9NA
UK

GE Healthcare Bio-Sciences
Corp.
800 Centennial Avenue
P.O. Box 1327
Piscataway
NJ 08855-1327
USA

GE Healthcare Bio-Sciences KK
Sanken Bldg. 3-25-1
Hyakunincho Shinjuku-ku
Tokyo 169-0073
Japan

**GE Healthcare
regional office
contact numbers:****Asia Pacific**

Tel: + 85 65 6 275 1830
Fax: +85 65 6 275 1829

Australasia

Tel: + 61 2 8820 8299
Fax: +61 2 8820 8200

Austria

Tel: 01 /57606 1613
Fax: 01 /57606 1614

Belgium

Tel: 0800 73 890
Fax: 02 416 82 06

Canada

Tel: 1 800 463 5800
Fax: 1 800 567 1008

Central, East, & South**East Europe**

Tel: +43 1 972720
Fax: +43 1 97272 2750

Denmark

Tel: 45 70 25 24 50
Fax: 45 16 24 24

Eire

Tel: 1 800 709992
Fax: 0044 1494 542010

Finland & Baltics

Tel: +358-(0)9-512 39 40
Fax: +358 (0)9 512 39 439

France

Tel: 01 6935 6700
Fax: 01 6941 9677

Germany

Tel: 0800 9080 711
Fax: 0800 9080 712

Greater China

Tel: +852 2100 6300
Fax: +852 2100 6338

Italy

Tel: 02 26001 320
Fax: 02 26001 399

Japan

Tel: +81 3 5331 9336
Fax: +81 3 5331 9370

Korea

Tel: 82 2 6201 3700
Fax: 82 2 6201 3803

Latin America

Tel: +55 11 3933 7300
Fax: + 55 11 3933 7304

Middle East & Africa

Tel: +30 210 9600 687
Fax: +30 210 9600 693

Netherlands

Tel: 0800 82 82 82 1
Fax: 0800 82 82 82 4

Norway

Tel: +47 815 65 777
Fax: 47 815 65 666

Portugal

Tel: 21 417 7035
Fax: 21 417 3184

**Russia & other C.I.S.
& N.I.S**

Tel: +7 (495) 956 5177
Fax: +7 (495) 956 5176

Spain

Tel: 902 11 72 65
Fax: 935 94 49 65

Sweden

Tel: 018 612 1900
Fax: 018 612 1910

Switzerland

Tel: 0848 8028 10
Fax: 0848 8028 11

UK

Tel: 0800 515 313
Fax: 0800 616 927

USA

Tel: +1 800 526 3593
Fax: +1 877 295 8102

<http://www.gehealthcare.com/lifesciences>

GE Healthcare UK Limited

Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA
UK



imagination at work